AR099890A1 - Inhibidores de histona demetilasas - Google Patents

Inhibidores de histona demetilasas

Info

Publication number
AR099890A1
AR099890A1 ARP150100947A ARP150100947A AR099890A1 AR 099890 A1 AR099890 A1 AR 099890A1 AR P150100947 A ARP150100947 A AR P150100947A AR P150100947 A ARP150100947 A AR P150100947A AR 099890 A1 AR099890 A1 AR 099890A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
aryl
heteroaryl
alkynyl
alkenyl
Prior art date
Application number
ARP150100947A
Other languages
English (en)
Inventor
Labelle Marc
Zhang Rui
D Martyr Cuthbert
Saraswat Neerja
Boesen Thomas
Original Assignee
Epitherapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitherapeutics Aps filed Critical Epitherapeutics Aps
Publication of AR099890A1 publication Critical patent/AR099890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/48—Aldehydo radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en donde Q se selecciona CO₂H, -CH=NR¹², -W, -CHR²⁰NR²¹R¹³, -CH=O y -CH(OR¹⁷)₂; A se selecciona de -C(R²ᵃ)₂C(O)-, -C(R²)₂C(R²)₂C(O)-, -Z-cicloalquileno C₃₋₁₀, -Z-heterociclileno, -Z-heteroarileno y -Z-arileno, cuyos -Z-cicloalquileno, -Z-heterociclileno, -Z-heteroarileno y -Z-arileno pueden estar opcionalmente sustituidos con uno o varios R³ y pueden formar una estructura cíclica o heterocíclica con Y, en donde dicha estructura cíclica o heterocíclica formada con Y se fusiona opcionalmente con un grupo arilo o heteroarilo opcionalmente sustituido; Z se selecciona de alquileno C₁₋₄, alqueneno C₂₋₅, alquineno C₂₋₅, heterociclileno y cicloalquileno C₃₋₆; cada M se selecciona, de modo independiente, CH o N; Y se selecciona de -H, -NR⁶R⁷, -OR⁷, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, heterociclilo, heteroarilo y arilo, cuyos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, heteroarilo y arilo pueden estar opcionalmente sustituidos con uno o varios R³; R¹ se selecciona de -H, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, cuyos alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de -OH, arilo, alcoxi C₁₋₆, heteroarilo, ariloxi, heteroariloxi, -NR⁶R⁷, F y cicloalquilo C₃₋₆; o con mayor preferencia, se selecciona de -H y alquilo C₁₋₄; o con -A-Y forma un nitrógeno que contiene grupo heterocíclico opcionalmente sustituido donde la sustitución opcional puede ser alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, alcoxi C₁₋₆, hidroxialquilo C₁₋₆, arilo, -C(=O)NR⁶R⁷, -NR⁶R⁷, -OH y halógeno, cuyos alquilo, alquenilo, alquinilo, cicloalquilo y arilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de -OH, arilo, alcoxi C₁₋₆, heteroarilo, ariloxi, heteroariloxi, -NR⁶R⁷, F y cicloalquilo C₃₋₆; o dicho nitrógeno que contiene grupo heterocíclico opcionalmente sustituido formado con -A-Y se fusiona opcionalmente con un grupo arilo o heteroarilo opcionalmente sustituido; o con R¹⁸ forma un nitrógeno que contiene grupo heterocíclico opcionalmente sustituido donde la sustitución opcional puede ser alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈ o cicloalquilo C₃₋₁₀, cuyos alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de -OH, arilo, alcoxi C₁₋₆, heteroarilo, ariloxi, heteroariloxi, -NR⁶R⁷, F y cicloalquilo C₃₋₆; R² se selecciona de -H, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈ y cicloalquilo C₃₋₁₀, cuyos alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de -OH, arilo, alcoxi C₁₋₆, heteroarilo, ariloxi, heteroariloxi, F y cicloalquilo C₃₋₆, -Z-heterociclilo, -Z-arilo, -Z-heteroarilo, -Z-NR⁶R⁷, -Z-C(=O)-NR⁶R⁷, -Z-NR⁶-C(=O)-R⁷, -Z-C(=O)-R⁷, -Z-OR⁷, halógeno, -Z-SR⁷, -Z-SOR⁷, -Z-SO₂R⁷, -Z-SO₂NR⁶R⁷ y -Z-COOR⁷; de modo alternativo, R² puede formar una estructura cíclica o heterocíclica con otros R², R¹, R¹⁸ o Y; R²ᵃ se selecciona de -H, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈ y cicloalquilo C₃₋₁₀, cuyos alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de -OH, arilo, alcoxi C₁₋₆, heteroarilo, ariloxi, heteroariloxi, F y cicloalquilo C₃₋₆, -Z-heterociclilo, -Z-arilo, -Z-heteroarilo, -Z-NR⁶R⁷, -Z-C(=O)-NR⁶R⁷, -Z-NR⁶-C(=O)-R⁷, -Z-NR⁶-C(=O)-OR⁷, -Z-C(=O)-OR⁷, -Z-OR⁷, halógeno, -Z-SR⁷, -Z-SOR⁷, -Z-SO₂R⁷, -Z-SO₂NR⁶R⁷ y -Z-COOR⁷; siempre que los dos grupos R²ᵃ son ambos no hidrógeno o uno de R²ᵃ forma un anillo con R¹ o R¹⁸; cada R³ se selecciona, de modo independiente, de alquilo C₁₋₆, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-arilo, -Z-heteroarilo, -Z-NR⁶R⁷, -Z-C(=O)-NR⁶R⁷, -Z-NR⁶-C(=O)-R⁷, -Z-NR⁶-C(=O)-OR⁷, -Z-C(=O)-R⁷, -Z-OR⁷, halógeno, -Z-SR⁷, -Z-SOR⁷, -Z-SO₂R⁷, -Z-SO₂NR⁶R⁷ y -Z-COOR⁷, en donde cualquier heterociclilo puede estar sustituido con uno o varios R⁴ y en donde cualquier heteroarilo y cualquier arilo puede estar sustituido con uno o varios R⁵; Z se selecciona de un enlace simple, alquileno C₁₋₄, heterociclileno y cicloalquileno C₃₋₆; cada R⁴ se selecciona, de modo independiente, de alquilo C₁₋₆, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₁₀, NR⁶R⁷, C(=O)-NR⁶R⁷, NR⁶-C(=O)-R⁷, Z-C(=O)-R⁷, -Z-C(=O)-H, OR⁷, halógeno, SR⁷, SOR⁷, SO₂R⁷, SO₂NR⁶R⁷ y COOR⁷ y -OH; cada R⁵ se selecciona, de modo independiente, de alquilo C₁₋₆, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₆, -Z-C(=O)-NR⁶R⁷, -Z-NR⁶-C(=O)-R⁷, -Z-C(=O)-R⁷, -Z-C(=O)OR⁷, -Z-NR⁶C(=O)OR⁷, OR⁷, -CN y halógeno; cada uno de R⁶ y R⁷ se selecciona, de modo independiente, de hidrógeno, donde opcionalmente no son ambos hidrógeno, alquilo C₁₋₈, fluoroalquilo C₁₋₄, perfluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-heteroarilo y -Z-arilo, cuyos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, heteroarilo y arilo pueden estar opcionalmente sustituidos con uno o varios R⁸ seleccionados de modo independiente; o, de modo alternativo, R⁶ y R⁷ pueden formar, junto con el átomo de N al que están unidos, un anillo N-heterocíclico opcionalmente sustituido con uno o varios R⁸ seleccionados de modo independiente; cada R⁸ se selecciona, de modo independiente, de alquilo C₁₋₆, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-heteroarilo, -Z-arilo, -Z-NR¹⁰R¹¹, -Z-C(=O)-NR¹⁰R¹¹, -Z-OR⁹, halógeno, -CN, -Z-SR⁹, -Z-SOR⁹, -Z-SO₂R⁹ y -Z-COOR⁹, cuyos alquilo, alquenilo, alquinilo, cicloalquilo, heterocíclicos, heteroarilo y arilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de alquilo C₁₋₄, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, cicloalquilo C₃₋₆, -Z-heterociclilo, -Z-heteroarilo, -Z-arilo, -Z-NR¹⁰R¹¹, -Z-C(=O)-NR¹⁰R¹¹, -Z-OR⁹, halógeno, -CN, -Z-SR⁹, -Z-SOR⁹, -Z-SO₂R⁹ y -Z-COOR⁹; en donde cualquier heterociclilo puede también estar sustituido con uno o varios R⁴ como se definió con anterioridad y en donde cualquier heteroarilo y cualquier arilo también puede estar sustituido con uno o varios R⁵ como se definió con anterioridad; cada R⁹ se selecciona, de modo independiente, de -H, alquilo C₁₋₈, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-arilo y -Z-heteroarilo, en donde cualquier heterociclilo puede estar sustituido con uno o varios R⁴ como se definió con anterioridad y en donde cualquier heteroarilo y cualquier arilo puede estar sustituido con uno o varios R⁵ como se definió con anterioridad; cada uno de R¹⁰ y R¹¹ se selecciona, de modo independiente, de -H, alquilo C₁₋₆, fluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, heterociclilo, heteroarilo y arilo, en donde cualquier heterociclilo puede estar sustituido con uno o varios R⁴ como se definió con anterioridad y en donde cualquier heteroarilo y cualquier arilo puede estar sustituido con uno o varios R⁵ como se definió con anterioridad, o, de modo alternativo, R¹⁰ y R¹¹ pueden formar, junto con el átomo de N al que están unidos, un anillo N-heterocíclico opcionalmente de 5 a 7 miembros, opcionalmente sustituido con uno o varios R⁴ como se definió con anterioridad; cuando Q es -CH=NR¹², R¹² se selecciona de alquilo C₁₋₁₀, alquenilo C₂₋₁₀, alquinilo C₂₋₁₀, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-arilo, -Z-heteroarilo, -Z-NR⁶R⁷, -Z-C(=O)-NR⁶R⁷, -Z-NR⁶-C(=O)-R⁷, -Z-C(=O)-R⁷, -Z-OR⁷, halógeno, -Z-SR⁷, -Z-SOR⁷, -Z-SO₂R⁷ y -Z-COOR⁷, cuyos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, heteroarilo y arilo pueden estar opcionalmente sustituidos con uno o varios R³; cuando Q es -CHR²⁰NR²¹R¹³, R¹³ se selecciona de hidrógeno, -C(O)R⁷, -C(O)C(O)R⁷, -C(O)C(O)OR⁷, alquilo C₁₋₈, fluoroalquilo C₁₋₄, perfluoroalquilo C₁₋₄, hidroxialquilo C₁₋₄, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, -Z-heterociclilo, -Z-arilo y -Z-heteroarilo, cuyos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo pueden estar opcionalmente sustituidos con uno o varios seleccionados de modo independiente R⁸ o es -CR¹⁴R¹⁵-NR⁶R⁷, -CR¹⁴R¹⁵CN o -CR¹⁴R¹⁵OR⁷, en donde cada uno de R¹⁴ y R¹⁵ se selecciona, de modo independiente, de -H, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₁₀, heterociclilo, heteroarilo y arilo y en donde R¹⁴ y R¹⁵ junto con el átomo de carbono interviniente pueden designar un anillo cicloalquilo C₃₋₁₀ o cicloalquenilo C₅₋₁₀, cuyos alquilo, alquenilo, alquinilo, cicloalquilo (anillo), anillo cicloalquenilo, heterociclilo, heteroarilo y arilo pueden estar opcionalmente sustituidos con uno o varios R³; R²⁰ y R²¹ son hidrógeno o forman juntos un grupo a 1,3-diaza-C₅₋₇-cicIoalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R⁶ y que opcionalmente contiene uno o dos grupos oxo; un grupo 1,3-tiaza-C₅₋₇-cicloalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R³ y que opcionalmente contiene uno o dos grupos oxo; un grupo 1,3-oxaza-C₅₋₇-cicloalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R⁶ y que opcionalmente contiene uno o dos grupos oxo, en donde en todas las tres instancias, dos R³ en el mismo átomo de carbono pueden formar juntos un grupo espiro; cuando Q es W, W se selecciona de un grupo 1,3-diaza-C₅₋₇-cicloalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R³ y que opcionalmente contiene uno o dos grupos oxo; un grupo 1,3-tiaza-C₅₋₇-cicloalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R³ y que opcionalmente contiene uno o dos grupos oxo; un grupo 1,3-oxaza-C₅₋₇-cicloalqu-2-ilo que está N-sustituido con R¹⁶ y opcionalmente también sustituido con uno o varios R⁶ y que opcionalmente contiene uno o dos grupos oxo, en donde en todas las tres instancias, dos R³ en el mismo átomo de carbono pueden formar juntos un grupo espiro; R¹⁶ se selecciona de hidrógeno, -C(O)R⁷, -C(O)C(O)R⁷, -C(O)C(O)OR⁷ y -C(O)C(O)NR⁶R⁷; cuando Q es -CH(OR¹⁷)₂, cada R¹⁷ es, de modo independiente, R³ o en donde dos sustituyentes de R¹⁷ junto con el -O-CH(-)-O- interviniente pueden formar un heterociclilo opcionalmente sustituido con uno o varios R³ y que contienen hasta dos grupos oxo; R¹⁸ se selecciona de hidrógeno, alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, alquenilo C₂₋₇, alquinilo C₂₋₇, cicloalquilo C₃₋₇, oxialquilo C₃₋₇ y pueden formar una estructura cíclica o heterocíclica con A, Y o R¹; uno de sus isómeros o una mezcla de sus isómeros o una de sus sales o solvatos o profármacos farmacéuticamente aceptables.
ARP150100947A 2014-03-31 2015-03-30 Inhibidores de histona demetilasas AR099890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972972P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
AR099890A1 true AR099890A1 (es) 2016-08-24

Family

ID=52823887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100947A AR099890A1 (es) 2014-03-31 2015-03-30 Inhibidores de histona demetilasas

Country Status (8)

Country Link
US (1) US20170369444A1 (es)
EP (1) EP3126345A1 (es)
JP (1) JP2017512804A (es)
AR (1) AR099890A1 (es)
AU (2) AU2015241022A1 (es)
CA (1) CA2943824A1 (es)
TW (1) TW201625535A (es)
WO (1) WO2015153498A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2903968T3 (pl) 2012-10-02 2017-05-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
JP6514117B2 (ja) 2013-02-27 2019-05-15 エピセラピューティクス アーペーエス ヒストン脱メチル化酵素の阻害剤
EA201790154A1 (ru) 2014-08-27 2017-08-31 Джилид Сайэнс, Инк. Соединения и способы для ингибирования гистоновых деметилаз
WO2017198785A1 (en) * 2016-05-18 2017-11-23 Ieo - Istituto Europeo Di Oncologia S.R.L. Oxime derivatives useful as inhibitors of histone demethylase kdm4c
WO2017214413A1 (en) * 2016-06-08 2017-12-14 Chrysalis, Inc. Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors
EP3600301B1 (en) * 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
EP3630079A4 (en) * 2017-05-31 2021-02-24 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASE (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSED LARGE B-CELL LYMPHOMA
ES2708900A1 (es) * 2017-10-10 2019-04-11 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Nuevos derivados de gramina con efecto protector de la actividad fosfatasa, y su aplicacion en el tratamiento de enfermedades humanas
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3833347A4 (en) * 2018-08-06 2022-04-27 Dana-Farber Cancer Institute, Inc. HISTONE-DEMETHYLAS-5 INHIBITORS AND USES THEREOF
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
JP7237311B2 (ja) * 2019-06-06 2023-03-13 京都府公立大学法人 化合物、医薬組成物、ｋｄｍ５ｃ阻害剤及び抗うつ剤
CN112844472B (zh) * 2021-01-15 2023-05-23 深圳市宝安区新材料研究院 一种手性咪唑脲类催化剂的制备方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8717374D0 (en) * 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
SI2130537T1 (sl) 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
JP2008013705A (ja) * 2006-07-07 2008-01-24 Fujifilm Corp インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法及び平版印刷版
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
TW201022230A (en) * 2008-08-28 2010-06-16 Organon Nv 1-(4-ureidobenzoyl)piperazine derivatives
US20110263564A1 (en) * 2008-10-29 2011-10-27 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
JP2010202575A (ja) * 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9365553B2 (en) * 2010-05-27 2016-06-14 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and H1 receptor antagonist
WO2012007008A1 (en) * 2010-07-15 2012-01-19 Epitherapeutics Aps Inhibitors of hdme
IT1403156B1 (it) * 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
EP2772490B1 (en) * 2011-10-27 2016-04-06 Astellas Pharma Inc. Aminoalkyl-substituted n-thienyl benzamide derivative
CN102585150B (zh) * 2012-02-01 2013-09-04 嘉兴学院 织物涂饰用阴离子水性聚氨酯分散体的制备方法
WO2013129435A1 (ja) * 2012-02-28 2013-09-06 協和発酵キリン株式会社 縮環チオフェン誘導体
PL2903968T3 (pl) * 2012-10-02 2017-05-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
JP6514117B2 (ja) * 2013-02-27 2019-05-15 エピセラピューティクス アーペーエス ヒストン脱メチル化酵素の阻害剤
CN103436254B (zh) * 2013-08-19 2014-10-08 中国科学院合肥物质科学研究院 一种功能化多元氮杂环荧光探针、其制备方法及其用途

Also Published As

Publication number Publication date
EP3126345A1 (en) 2017-02-08
TW201625535A (en) 2016-07-16
US20170369444A1 (en) 2017-12-28
JP2017512804A (ja) 2017-05-25
WO2015153498A1 (en) 2015-10-08
CA2943824A1 (en) 2015-10-08
AU2015241022A1 (en) 2016-10-27
AU2018200982A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AR099890A1 (es) Inhibidores de histona demetilasas
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR105575A1 (es) COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa
AR092742A1 (es) Piridinonas antifibroticas
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR117617A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR105104A1 (es) Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR111689A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de irak4
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR092347A1 (es) Derivados de azaindol
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR105875A1 (es) Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR106297A1 (es) Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9
AR091498A1 (es) DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR093503A1 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure